A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of TRN-002 (crofelemer) for the symptomatic treatment of diarrhea-predominant irritable bowel syndrome (d-IBS) in females

Trial Profile

A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of TRN-002 (crofelemer) for the symptomatic treatment of diarrhea-predominant irritable bowel syndrome (d-IBS) in females

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs Crofelemer (Primary)
  • Indications Irritable bowel syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Trine Pharmaceuticals
  • Most Recent Events

    • 20 Nov 2015 Last checked against ClinicalTrials.gov record.
    • 24 Dec 2008 Results have been published in Digestion - International Journal of Gastroenterology, according to a Napo Pharmaceuticals media release.
    • 01 Jan 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top